

November 27, 2013

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (AB-05)

LATIGLUTENASE

PRONUNCIATION

la" ti gloo' te nase

THERAPEUTIC CLAIM

Treatment of Celiac disease

CHEMICAL NAMES

(A)

1. procysteine proteinase (synthetic *Hordeum vulgare* isoenzyme EP-B2)
2. l-methionylglycyl-l-seryl-l-serylhexa-l-histidyl-l-seryl-l-serylglycyl-l-leucyl-l-valyl-l-prolyl-l-arginylglycyl-l-seryl-l-histidyl-l-methionyl-l-alanyl-l-seryl-l-methionyl-l-threonylglycylglycyl-l-glutamyl-l-glutamyl-l-methionylglycyl-l-arginyl-l-aspartyl-l-prolyl-des-(1-25)-cysteine proteinase EP-B 2 precursor (*Hordeum vulgare*) fusion protein with l-asparaginyl-tri-l-seryl-l-valyl-l-aspartyl-l-lysyl-l-leucyl-tri-l-alanyl-l-leucyl-l-glutamylhexa-l-histidine

(B)

1. Peptidase, proline endo- (synthetic *Sphingomonas capsulata* precursor)
2. l-methionyl-l-valyl-l-seryl-l-serylhexa-l-histidyl-l-seryl-l-serylglycyl-l-leucyl-l-valyl-l-prolyl-l-arginylglycyl-l-seryl-des-1-l-methionine-prolyl oligopeptidase precursor (*Novosphingobium capsulatum*)

STRUCTURAL FORMULAE

Cysteine proteinase EP-B 2 (*Hordeum vulgare*)

MGSSHHHHHH	SSGLVPRGSH	MASMTGGQQM	GRDPCSAIPM	EDKDLESEEA	50
LWDLYERWQS	AHRVRRHHAE	KHRRFGTFKS	NAHFIHSHNK	RGDHPYRLHL	100
NRFQDMDQAE	FRATFVGDRLR	RDTPSKPPSV	PGFMYAALNV	SDLPPSVDWR	150
QKGAVTGVKD	QGKCGSCWAF	STVVSVEGIN	AIRTGSLVSL	SEQELIDCDT	200
ADNDGCGGGL	MDNAFEYIKN	NGGLITEAAY	PYRAARGTCN	VARAAQNSPV	250
VVHIDGHQDV	PANSEEDLAR	AVANQPVSVA	VEASGKAFMF	YSEGVFTGEC	300
GTELDHGVAV	VGYGVAEDGK	AYWTVKNSWG	PSWGEQGYIR	VEKDSGASGG	350
LCGIAMEASY	PVKTYSKPKP	TPRRALGARE	SLNSSSVDKL	AAALEHHHHH	400
H					401

Disulfide bridges location

164-167 198-206 300-352

Prolyl endopeptidase (*Sphingomonas capsulata*)

MVSSHHHHHH	SSGLVPRGSK	NRLWLAMAAP	LALATPVAF	QTPPTLAKDQ	50
AMPSTLPPYPA	SPQVPLVEDH	FGEKVSDPWR	WLEADVRTDA	KVAAWVQAQS	100
AYTAAYLKQL	PERAALEKRM	KALIDYERFG	LPQRRGASVF	YSWNSGLMNQ	150
SQLLVVRPADA	PVGTKGRVLL	DPNTWAKDGA	TALDAWAASD	DGRLLAYSVQ	200
DGGSDDWRVTK	FVGVADGKPL	ADELKWKVFS	GLAWLGNLAL	LYSRFAEPKE	250
GQAFQALNYN	QTVWLHRLGT	PQSADQPVFA	TPELPKRGHG	ASVSSDGRWV	300
VITSSEGTDP	VNTVHVARVT	NGKIGPVTAL	IPDLKAQWDF	VDGVDQLWF	350
VSGDGAPLKK	IVRVDLGSGT	PRFDTVVPES	KDNLESVGIA	GNRLFASYIH	400
DAKSQVLAFFD	LDGKPAAGAVS	LPGIGSASGL	SGRPGDRHAY	LSFSSFTQPA	450

LATIGLUTENASE

N13/133

Page 2 of 2

TVLALDPATA	KTPWEPVHL	TFDPADFRVE	QVFYPSKDGT	KVPMFIVRRK	500
DAKGPLPTLL	YGYGGFNVAL	TPWFSAGFMT	WIDSGGAFAL	ANLRGGGEYG	550
DAWHDAGRRD	KKQNVFDDFI	AAGEWLIANG	VTPRHGLAIE	GGSNGLLIG	600
AVTNQRPDFL	AAASPAVGVM	DMLRFDQFTA	GRYWVDYGY	PEKEADWRVL	650
RRYSPYHNVR	SGVDYPAILV	TTADTDDRIV	PGHSLKYTAA	LQTAAIGPKP	700
HLIRIETRAG	HGSGKPIDKQ	IEETADVQAF	LAHFTGLTPR	P	741

MOLECULAR FORMULA

$C_{1898}H_{2908}N_{574}O_{588}S_{18}$
 $C_{3631}H_{5563}N_{1003}O_{1051}S_9$

MOLECULAR WEIGHTS

43.75 kDa
 80.37 kDa

TRADEMARK

None as yet

SPONSOR

Alvine Pharmaceuticals, Inc.

CODE DESIGNATIONS

ALV003

CAS REGISTRY NUMBER

1360452-96-5

UNII

090PL12YZJ

SCS